Asunto(s)
Antimetabolitos Antineoplásicos/efectos adversos , Capecitabina/efectos adversos , Neoplasias del Colon/tratamiento farmacológico , Desensibilización Inmunológica/métodos , Erupciones por Medicamentos/terapia , Hipersensibilidad Tardía/terapia , Piel/efectos de los fármacos , Anciano , Antimetabolitos Antineoplásicos/administración & dosificación , Antimetabolitos Antineoplásicos/inmunología , Capecitabina/administración & dosificación , Capecitabina/inmunología , Neoplasias del Colon/patología , Esquema de Medicación , Erupciones por Medicamentos/diagnóstico , Erupciones por Medicamentos/inmunología , Humanos , Hipersensibilidad Tardía/diagnóstico , Hipersensibilidad Tardía/inmunología , Tolerancia Inmunológica , Pruebas Intradérmicas , Masculino , Piel/inmunología , Piel/patología , Factores de Tiempo , Resultado del TratamientoRESUMEN
No disponible
Asunto(s)
Humanos , Masculino , Anciano , Hipersensibilidad a las Drogas/inmunología , Desensibilización Inmunológica/instrumentación , Desensibilización Inmunológica/métodos , Desensibilización Inmunológica , 35170/métodos , 35170/prevención & control , Antineoplásicos/efectos adversos , Antineoplásicos/inmunología , Antineoplásicos/uso terapéuticoRESUMEN
BACKGROUND/AIM: The consensus document for hypersensitivity reactions to nonsteroidal anti-inflammatory drugs (NSAIDs) proposed by the European Network for Drug Allergy (ENDA) interest group (2011) was revised in 2013. We aimed to evaluate the usability of the latest NSAID hypersensitivity classification of ENDA. METHOD: A total of 370 patients with a history of hypersensitivity reactions to NSAIDs among the 1250 outpatients referred for suspected drug allergy between July 2013 and June 2014 were evaluated, and 308 patients who were confirmed as having NSAID hypersensitivity were included in this study. After confirming the diagnosis, a single-blind placebo-controlled drug provocation test was performed with aspirin or diclofenac to categorize the patients according to the ENDA classification. The reactions not meeting the ENDA classification criteria were grouped as blended reactions. RESULTS: Among the 308 patients (224 female, mean age 42.12 ± 13.24), the leading cause of hypersensitivity reactions was metamizol (30.5%) followed by aspirin (30.2%). The most common NSAID hypersensitivity subgroup was SNIUAA (46.4%) and the least common type was SNIDR (1.6%). Cross-reactivity was identified in 50.3% of the patients. In five patients (1.6%), the hypersensitivity reactions to NSAIDs did not meet the ENDA classification: Three patients experienced anaphylaxis with different NSAIDs, one patient encountered anaphylaxis with one NSAID and urticaria with other NSAIDs, and the last patient had angioedema with different NSAIDs. CONCLUSION: The latest ENDA classification for NSAID hypersensitivity is generally a practical and useful instrument for clinicians. We only point out that anaphylaxis with different NSAIDs can be seen in a small group of patients.